Entries |
Document | Title | Date |
20080207719 | Treatment of Epilepsy - The disclosure relates to a method for the inhibition of the development of epilepsy with an alpha2-adrenoceptor antagonist or a pharmaceutically acceptable salt or ester thereof. | 08-28-2008 |
20080234342 | Skin Conditioning Compositions Containing Compounds for Mimicking the Effect on Skin of Retinoic Acid - A skin care product comprising from about 0.001% to about 10% of a retinoid, in combination with 0.0001% to a bout 50% of a combination of retinoid boosters. | 09-25-2008 |
20090118343 | TREATMENT OF SEVERE DISTAL COLITIS - This invention relates to methods and materials involved in the treatment of diseases with severe distal colitis component, and more specifically non-fungal and/or non-microbial induced mucositis of the distal intestinal tract. Kits and pharmaceutical compositions for medical treatments also are provided. | 05-07-2009 |
20090163566 | Imidazole Derivatives and their use for Modulating the Gabaa Receptor Complex - This invention relates to novel imidazole derivatives of the general formula (I): pharmaceutical compositions containing these compounds, and methods of treatment therewith. The compounds of the invention are useful in the treatment of central nervous system diseases and disorders, which are responsive to modulation of the GABA | 06-25-2009 |
20090186929 | Method and agent for inducing apoptosis/cell death in leukemia cells - A method for inducing apoptosis or cell death in leukemia cells includes inhibiting the production of nitric oxide (NO) by using a nitric oxide synthase (NOS) inhibitor. The NOS inhibitor includes a NOS1-specific inhibitor, such as N-[4-(2-{[(3-chlorophenyl)methyl]amino}ethyl)phenyl]-2-thiophenecarboximide dihydrochloride, [N | 07-23-2009 |
20090270474 | Therapeutic Agent for Keratoconjunctival Disorder - An object of the present invention is to discover a new use of eprosartan or a salt thereof. Eprosartan or a salt thereof exhibits an excellent improving effect in a corneal disorder model, and therefore is useful as a therapeutic agent for a keratoconjunctival disorder such as dry eyes, corneal ulcer, keratitis, conjunctivitis, superficial punctate keratopathy, corneal epithelial defects, conjunctival epithelial defects, keratoconjunctivitis sicca, superior limbic keratoconjunctivitis and filamentary keratitis. | 10-29-2009 |
20090281156 | ENHANCING PHOTOSTABILIZATION OF OXYMETAZOLINE - The photostability of oxymetazoline in a topical decongestant composition is enhanced by lowering the pH of the composition using a buffer solution. | 11-12-2009 |
20100004304 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MALIGNANT MELANOMA, BREAST, PROSTATE, COLON, PAPILLARY THYROID AND PANCREATIC CANCER - It is now recognized that chronic inflammation is an important risk factor for the development of cancer. The proinflammatory cytokine IL-6 is implicated in cancer because it is important for the activation of STAT, a key regulator of cancer growth, survival, metastasis, immune evasion and angiogenesis. Increased IL-6 and Stat-3 exists in vitro in pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells with high basal expression of Toll-like receptor 3 (TLR3) and Wnt5a. IL6/STAT3 activation, mediated by overexpressed TLR3 signaling, appears important in the tumor growth process, it may increase Wnt5a signaling, and be associated with increased cellular growth and migration. Using a novel inhibitor of pathologic TLR3 signaling (5-phenylmethimazole [C10]) we have demonstrated decreases in these markers plus suppression of cell growth and migration in human pancreatic cancer, malignant melanoma, papillary thyroid cancer, breast cancer, colon cancer, and prostate cancer cells. | 01-07-2010 |
20100004305 | NAPHTHYLMETHYLIMIDIZOLES AS THERAPEUTIC AGENTS - Disclosed herein is a compound of the formula (a): Therapeutic methods, compositions and medicaments related thereto are also disclosed. | 01-07-2010 |
20100069452 | MINERALOCORTICOID RECEPTOR MODULATORS - The present invention relates to diphenylmethyl imidazole mineralocorticoid receptor modulators compounds having the structure | 03-18-2010 |
20100168197 | MUSCARINIC RECEPTOR ANTAGONISTS - This present invention generally relates to muscarinic receptor antagonists, which are useful, among other uses, for the treatment of various diseases of the respiratory, urinary and gastrointestinal systems mediated through muscarinic receptors. The invention also relates to the process for the preparation of disclosed compounds, pharmaceutical compositions containing the disclosed compounds, and the methods for treating diseases mediated through muscarinic receptors. | 07-01-2010 |
20100168198 | Mitochondria-targeted antioxidant prodrugs and methods of use - The present invention is a mitochondria-targeted antioxidant prodrug useful for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. Antioxidant prodrugs of the invention are produced by modifying an antioxidant to a fatty acid so that the resulting prodrug is targeted to and activated by an enzyme of mitochondrial fatty acid beta-oxidation. | 07-01-2010 |
20100179205 | Composition for Enhanced Antiparasitic Activity - The invention relates to antiparasitic compositions comprising a combination of atipamezole or its pharmaceutically acceptable salt and amitraz and their use in a method to control ectoparasite infestations on animals. | 07-15-2010 |
20110021588 | SUBLINGUAL DEXMEDITOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF - Analgesic sublingual formulations of dexmedetomidine and methods of use thereof are provided for use in the prevention, treatment and management of pain and other conditions. | 01-27-2011 |
20110021589 | IMIDAZOLIC COMPOUNDS AND USE THEREOF AS ALPHA-2 ADRENERGIC RECEPTORS - The invention provides methods of treating a memory deficiency in a subject in need of such treatment, where the methods comprise administering to a subject an effective amount of a compound of formula (1): | 01-27-2011 |
20110071203 | TRANSMUCOSAL VETERINARY COMPOSITION COMPRISING DETOMIDINE - The present invention relates to a veterinary composition in a semisolid form adapted for transmucosal administration for providing sedation and analgesia in large animals such as horses and cattle. The semisolid transmucosal composition of the invention comprises detomidine or a pharmaceutically acceptable salt thereof as an active ingredient. The composition provides a rapid onset of action while having low irritation potential in the oral mucosa. | 03-24-2011 |
20110098330 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS - A compound having selective modulating activity at the alpha 2B and or alpha 2C adrenergic receptor subtypes is represented by the general Formula (1): wherein R | 04-28-2011 |
20110230534 | Composition For Local Anesthesia - An object of the present invention is to provide a composition for local anesthesia to be added to a local anesthetic drug, the composition showing a sustained local anesthetic effect and having high safety. The object is achieved by a composition for local anesthesia including a drug antagonistic to a systemic action of adrenaline, i.e., an α2 receptor agonist. The α2 receptor agonist can be added to a local anesthetic agent together with adrenaline or a salt thereof to reduce the amount of adrenaline to be added as compared to that of adrenaline or a salt thereof alone. As a result, a sustained local anesthetic effect is obtained and local anesthesia can be performed with high safety. | 09-22-2011 |
20120041042 | Scent Ectoparasiticidal Formulation - The present invention provides an improved-scent composition comprising metaflumizone, as well as a method for protecting against ectoparasite infestations in a warm-blooded animal. | 02-16-2012 |
20120202863 | Compositions and methods for treatment of glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine at near alkaline pH and extremely low concentrations. | 08-09-2012 |
20120202864 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine at acidic pH and extremely low concentrations. | 08-09-2012 |
20120202865 | SUBSTITUTED-ARYL-(IMIDAZOLE)-METHYL)-PHENYL COMPOUNDS AS SUBTYPE SELECTIVE MODULATORS OF ALPHA 2B AND/OR ALPHA 2C ADRENERGIC RECEPTORS - A compound having selective modulating activity at the alpha 2B and or alpha 2C adrenergic receptor subtypes is represented by the general Formula 1: | 08-09-2012 |
20120208858 | Pharmaceutical Cream Compositions of Oxymetazoline and Methods of Use - The present invention is directed to: a) a method of treating telangiectasia; b) a method of treating inflammatory lesions; and c) a method of treating two or more symptoms of rosacea selected from erythema, telangiectasia, or inflammatory lesions comprising topical administration of a pharmaceutical composition comprising oxymetazoline and a pharmaceutically acceptable excipient. | 08-16-2012 |
20120309804 | COMPOSITIONS AND METHODS FOR TREATMENT OF GLAUCOMA - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 12-06-2012 |
20120316210 | TOPICAL ANTIPARASITIC FORMULATIONS - This invention recites topical formulations comprising demiditraz, fipronil, an acid modifier, at least one veterinarily acceptable carrier, and optionally, at least one antioxidant for treating a parasitic infection or infestation in animals. | 12-13-2012 |
20130072532 | TOPICAL TRANSDERMAL DEXMEDETOMIDINE COMPOSITIONS AND METHODS OF USE THEREOF - Analgesic topical formulations of dexmedetomidine and methods of use thereof in the treatment and management of pain and other conditions. | 03-21-2013 |
20130096170 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE - The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery. | 04-18-2013 |
20130096171 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE - The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery. | 04-18-2013 |
20130096172 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE - The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery. | 04-18-2013 |
20130143938 | Compositions and Methods for the Treatment of Migraine - Pharmaceutical compositions for the treatment of nasal congestion or migraine, wherein the pharmaceutical compositions comprise low concentrations of a super-selective subclass of selective α-2 adrenergic receptor agonists. | 06-06-2013 |
20130237576 | Dexmedetomidine Premix Formulation - The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation. | 09-12-2013 |
20130338206 | TOPICAL LIQUID TO AMELIORATE PAIN AND PROMOTE HEALING OF BURN-INJURED SKIN - A novel method and composition is disclosed for treating burn injuries on human skin by promoting healing of the damaged skin. In particular, a topical liquid drug formulation is used to treat burn injuries caused by exposure of the skin to heat (thermal burns), the sun or ultraviolet radiation (sunburn), ionizing radiation (radiation burns), chemicals (chemical burns) and electricity (electrical burns). The topical burn treatment liquid contains clotrimazole as the active pharmaceutical ingredient to promote the healing of the burn damaged skin by reducing the edema, erythema, blistering, pain and other symptoms associated with burns, as well as preventing the spread of the burn damage and promoting healing. | 12-19-2013 |
20140005243 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE | 01-02-2014 |
20140107173 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 04-17-2014 |
20140155445 | Compounds and Methods for Treating Cancer and Diseases of the Central Nervous System - Disclosed are compounds of the general formula (I): | 06-05-2014 |
20140155446 | DEXMEDETOMIDINE PREMIX FORMULATION - The presently disclosed subject matter relates to pharmaceutical compositions comprising dexmedetomidine or a pharmaceutically acceptable salt thereof wherein the composition is formulated as a liquid for parenteral administration to a subject, and wherein the composition is disposed within a sealed container as a premixture. The pharmaceutical compositions can be used, for example, in perioperative care of a patient or for sedation. | 06-05-2014 |
20140163080 | Compositions and Methods for Treatment of Glaucoma - The invention provides α-2 adrenergic receptor agonist compositions and methods for treating glaucoma and other intraocular conditions. The preferred α-2 agonist used in the inventive compositions and methods is dexmedetomidine. | 06-12-2014 |
20140303220 | COMPOSITIONS COMPRISING AN ARYL PYRAZOLE AND A SUBSTITUTED IMIDAZOLE, METHODS AND USES THEREOF - This invention relates to compositions for combating parasites in animals, comprising 1-arylpyrazole compounds in combination with substituted imidazole compounds. This invention also provides for an improved methods for eradicating, controlling, and preventing parasite infestation in an animal comprising administering the compositions of the invention to an animal in need thereof. | 10-09-2014 |
20140350063 | BIOTHERAPEUTICS FOR THE TREATMENT OF INFECTIOUS DISEASES - An occlusive dressing made with an elastomeric gel and one or more active agents is described. The elastomeric gel contains a plasticizing oil phase and a block copolymer agent. Methods of preventing, treating, curing or mitigating an infectious disease and methods of making the dressings are also disclosed. | 11-27-2014 |
20160067220 | METHODS OF TREATING PEDIATRIC PATIENTS USING DEXMEDETOMIDINE - The presently disclosed subject matter relates to methods of administering an effective amount of dexmedetomidine to a pediatric patient in order to reduce the incidence of neurological damage. More particularly, the presently disclosed subject matter relates to methods of providing sedation or analgesia to a pediatric patient by administering a dexmedetomidine infusion and optionally a loading dose. The dexmedetomidine can be administered before, during, or after surgery. | 03-10-2016 |
20160106104 | SILICONE-BASED ANTIMICROBIAL COMPOSITION - The present invention relates to a composition, comprising:
| 04-21-2016 |
20160175285 | DEXMEDETOMIDINE PREMIX FORMULATION | 06-23-2016 |
20220133695 | SINGLE-DOSE PACKAGED CLOTRIMAZOLE LIQUID COMPOSITION - It relates to a single-dose packaging unit which is a blow-fill-seal (BFS) container which comprises a sterile pharmaceutical or veterinary liquid composition which is a solution, wherein a) the composition comprises a therapeutically effective amount of clotrimazole or a pharmaceutically or veterinary acceptable salt thereof, together with one or more pharmaceutically or veterinary acceptable excipients or carriers, and b) the container has a volume from 0.05 to 8 mL, with the condition that the water content of the composition is equal to or lower than 4% by weight with respect to the total composition weight. It also relates to a secondary packaging comprising one or more single-dose packaging units. | 05-05-2022 |